egfrin7

EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.

VEGFR-IN-7 (Compound 2) is a VEGFR inhibitor that exhibits a modest inhibitory effect on angiogenesis. It holds potential for cardiovascular disease research.

EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 3.7 μM, and it has research value in chordoma.

EGFR-IN-70 is a potent EGFR inhibitor with IC 50 values of 23.6 and 307.5 nM for EGFR LR/TM/CS and EGFR WT , respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR . EGFR-IN-70 can be used for cancer research .

EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, with an IC50 value of 119 nM [1].

EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM. It effectively induces apoptosis in cancer cells.

EGFR-IN-75, an inhibitor of both EGFR WT and EGFR T790M, exhibits anticancer and antioxidant properties with IC50 values of 0.28 μM and 5.02 μM, respectively.

EGFR-IN-76 is a potent EGFR inhibitor.

EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer. It exhibits anti-proliferative properties, impedes EGFR phosphorylation, and induces G2/M phase cell cycle arrest [1].

EGFR-IN-79 (compound 21), an EGFR inhibitor, exhibits antitumor activity through ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. It effectively induces cell death in proliferating and quiescent zones of EJ28 spheroids and demonstrates a safety profile in zebrafish-based models [1].